LexDanaLexDanabeta
Inventor

Nabil Hanna

Inventor
Rancho Santa Fe, CA, US

Overview

51→
Patents
1982–2010
Patent span
Human necessities
Primary field (CPC A)

Patents· 51 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
C07KPeptides25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C12NMicroorganisms or enzymes8%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%
C07DHeterocyclic compounds4%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
Y02ATechnologies for adaptation to climate change1%
A01KAnimal husbandry1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
PatentTitleYear
7,744,877'Expression and use of anti-CD20 Antibodies'20107,510,713'Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies'20097,510,712'Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies'20097,501,264'Methods of producing 7C10 and 16C10 CD80-specific antibodies'20097,491,393'Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies'20097,452,534'Recombinant anti-CD4 antibodies for human therapy'20087,425,447'Host cells expressing 7C10 and 16C10 CD80-specific antibodies'20087,422,739'Anti-CD20 antibodies'20087,417,128'7C10 and 16C10 CD80-specific antibodies'20087,414,123'Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies'20087,381,560'Expression and use of anti-CD20 antibodies'20087,338,658'Recombinant anti-CD4 antibodies for human therapy'20087,323,170'Anti-CD80 antibodies'20087,319,139'TAG-72 specific CH2 domain deleted antibodies'20087,294,753'Method for preparing anti-MIF antibodies'20077,192,585'CD80 specific antibodies'20077,175,847'Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4'20077,153,508'Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4'20067,122,187'Treating autoimmune diseases with humanized anti-CD40L antibody'20067,074,406'Treating allergic diseases with humanized anti-CD40L antibody'20066,998,125'Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis'20066,896,885'Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma'20056,897,044'Production of tetravalent antibodies'20056,893,638'Methods for treating b cell lymphoma using CD80-specific antibodies'20056,709,654'Treatment of psoriasis using anti-B7.1 (CD80) antibodies'20046,682,734'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'20046,506,383'Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies'20036,440,418'Methods of treating autoimmune diseases with gp39-specific antibodies'20026,399,061'Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma'20026,136,310'Recombinant anti-CD4 antibodies for human therapy'20006,113,898'Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies'20006,001,358'Humanized antibodies to human gp39, compositions containing thereof'19995,843,439'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,776,456'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,756,096'Recombinant antibodies for human therapy'19985,750,105'Recombinant antibodies for human therapy'19985,736,137'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,693,780'Recombinant antibodies for human therapy'19975,681,722'Recombinant antibodies for human therapy'19975,658,570'Recombinant antibodies for human therapy'19975,317,019'Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages'19945,145,858'Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors'19925,134,150'Inhibition of the 5-lipoxygenase pathway'19925,002,941'Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors'19914,794,114'Inhibition of interleukin-1 production by monocytes and/or macrophages'19884,780,470'Inhibition of interleukin-1 by monocytes and/or macrophages'19884,778,806'Inhibition of interleukin-1 production by monocytes and/or macrophages'19884,751,310'Inhibition of the 5-lipoxygenase pathway'19884,719,218'Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor'19884,686,231'Inhibition of 5-lipoxygenase products'19874,319,733'Locking spring clip'1982

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1982Patents assigned to AMP INC (1)· patent assignee history
1987–1988Patents assigned to SMITHKLINE BECKMAN CORP (6)· patent assignee history
1987–1992Based in Berwyn, PA, US· patent location history
1991–1994Patents assigned to SMITHKLINE BEECHAM CORP (4)· patent assignee history
1997–2004Patents assigned to IDEC PHARMA CORP (14)· patent assignee history
1997–2006Based in Olivenhain, CA, US· patent location history
1999–2006Based in Olivenhian, CA, US· patent location history
2000–2009Based in Rancho Santa Fe, CA, US· patent location history
2005–2010Patents assigned to BIOGEN IDEC INC (23)· patent assignee history
2010Based in Olivenham, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BIOGEN IDEC INC232005–2010
IDEC PHARMA CORP141997–2004
SMITHKLINE BECKMAN CORP61987–1988
SMITHKLINE BEECHAM CORP41991–1994
AMP INC11982
Locations
LocationPatentsSpan
Rancho Santa Fe, California, US212000–2009
Olivenhain, California, US121997–2006
Berwyn, Pennsylvania, US91987–1992
Olivenhian, California, US41999–2006
Olivenham, California, US12010